Mobia to raise USD 160 million in US IPO

Mobia Medical Inc., a maker of medical devices to help stroke survivors, is seeking to raise as much as $160 million in a US initial public offering.

The Austin-based firm plans to market 10 million shares at $14 to $16 each, according to its filing Monday with the US Securities and Exchange Commission. At the top of the price range, Mobia would have a market value of about $529 million, based on the outstanding shares listed in the filing.

Mobia’s proposed listing adds to the handful of new entrants in the medical technology sector so far in 2026. Diabetes-management firm MiniMed Group Inc. raised $560 million in its IPO following its separation from health-care giant Medtronic Plc, while medical device maker Alamar Biosciences Inc. raised $220 million in its debut.

The company was incorporated in 2007 as MicroTransponder Inc. before changing its name earlier this year. Mobia’s Vivistim System was approved by the US Food and Drug Administration as a solution for chronic ischemic stroke survivors with moderate to severe upper extremity impairments.

Mobia had a net loss of $46.5 million on sales of $32 million in 2025, compared with a net loss of $24.6 million on sales of $15.6 million a year earlier, its filing showed.

The offering is being led by Bank of America Corp., JPMorgan Chase & Co. and Goldman Sachs Group Inc. The company plans for its shares to trade on the Nasdaq Global Select Market under the symbol MOBI. Bloomberg